TGFB1 and Hepatic fibrosis: αLA inhibits thioacetamide (TAA)-induced liver fibrosis in rats by inhibiting TGF-β1 and the MAP kinase signaling pathway [25] and inhibits bile duct ligation (BDL)-induced hepatic fibrosis in mice by inhibiting TGF-β signaling pathway [13].